220 related articles for article (PubMed ID: 16300418)
1. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
Hong SH; Shepherd MD; Scoones D; Wan TT
J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
[TBL] [Abstract][Full Text] [Related]
2. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
3. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
4. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
[TBL] [Abstract][Full Text] [Related]
5. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
Levy MS
Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
[TBL] [Abstract][Full Text] [Related]
6. Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade.
Grabowski H; Vernon J
Pharmacoeconomics; 1996; 10 Suppl 2():110-23. PubMed ID: 10163428
[TBL] [Abstract][Full Text] [Related]
7. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
8. A Method for Approximating Future Entry of Generic Drugs.
Beall RF; Darrow JJ; Kesselheim AS
Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
[TBL] [Abstract][Full Text] [Related]
9. Generic script share and the price of brand-name drugs: the role of consumer choice.
Rizzo JA; Zeckhauser R
Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
[TBL] [Abstract][Full Text] [Related]
10. Strategies That Delay Market Entry of Generic Drugs.
Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
[TBL] [Abstract][Full Text] [Related]
11. Recent trends in brand-name and generic drug competition.
Grabowski H; Long G; Mortimer R
J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785
[TBL] [Abstract][Full Text] [Related]
12. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
13. Reference pricing of pharmaceuticals.
Brekke KR; Königbauer I; Straume OR
J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
[TBL] [Abstract][Full Text] [Related]
14. The Evolution of Supply and Demand in Markets for Generic Drugs.
Frank RG; McGuire TG; Nason I
Milbank Q; 2021 Sep; 99(3):828-852. PubMed ID: 34075623
[TBL] [Abstract][Full Text] [Related]
15. Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.
Huskamp HA
Health Aff (Millwood); 2006; 25(3):635-46. PubMed ID: 16684726
[TBL] [Abstract][Full Text] [Related]
16. Strategic options for brand-name prescription drugs when patents expire.
Mehta SC; Mehta SS
Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
[TBL] [Abstract][Full Text] [Related]
17. Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition.
Zhang JX
PLoS One; 2020; 15(6):e0234463. PubMed ID: 32525965
[TBL] [Abstract][Full Text] [Related]
18. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
Magazzini L; Pammolli F; Riccaboni M
Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
[TBL] [Abstract][Full Text] [Related]
19. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
Cheng N; Banerjee T; Qian J; Hansen RA
J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
[TBL] [Abstract][Full Text] [Related]
20. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
